In vitro studies have shown that platinum resistance is associated with ERCC1 mRNA expression in ovarian, cervical, testicular, bladder, and non-small-cell lung cancer cell lines.[12,13] Additionally, some clinical studies have revealed that ERCC1 expression is correlated with resistance to platinum-based chemotherapy and poor prognosis in patients with several types of tumor,[12,14–17] suggesting that the DNA-damage repair capacity plays an important role and is involved in resistance to cisplatin-based chemotherapy or radiotherapy. Here, ERCC1 is linked to non-small cell lung carcinoma.